Literature DB >> 2643055

Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts.

T A Partridge1, J E Morgan, G R Coulton, E P Hoffman, L M Kunkel.   

Abstract

An important corollary to the recent advances in our understanding of the primary cause of Duchenne muscular dystrophy, is the validation of genuine genetic homologues as animal models of the disease in which potential therapies can be tested. The persistent skeletal muscle necrosis that characterizes human Duchenne muscular dystrophy is also seen in the mdx mouse and is, in both, a consequence of a deficiency of dystrophin, probably within the muscle fibres themselves. As injected muscle precursor cells of one genotype can fuse with host muscle fibres of a different genotype and express the donor genes, we decided to test grafts of normal muscle precursor cells to see if they could induce synthesis of dystrophin in innately dystrophin-deficient mdx muscle fibres. We show that injected normal muscle precursor cells can fuse with pre-existing or regenerating mdx muscle fibres to render many of these fibres dystrophin-positive and so to partially or wholly rescue them from their biochemical defect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643055     DOI: 10.1038/337176a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  218 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration.

Authors:  Ingo Riederer; Elisa Negroni; Maximilien Bencze; Annie Wolff; Ahmed Aamiri; James P Di Santo; Suse D Silva-Barbosa; Gillian Butler-Browne; Wilson Savino; Vincent Mouly
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 3.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

4.  Transferring myoblasts in Duchenne dystrophy.

Authors:  V Dubowitz
Journal:  BMJ       Date:  1992-10-10

Review 5.  The muscular dystrophies.

Authors:  V Dubowitz
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

6.  Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes.

Authors:  M D Grounds; K L Garrett; M C Lai; W E Wright; M W Beilharz
Journal:  Cell Tissue Res       Date:  1992-01       Impact factor: 5.249

Review 7.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

Review 8.  Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish.

Authors:  Louis M Kunkel; Estanislao Bachrach; Richard R Bennett; Jeffrey Guyon; Leta Steffen
Journal:  J Hum Genet       Date:  2006-04-01       Impact factor: 3.172

Review 9.  Update on the treatment of Duchenne muscular dystrophy.

Authors:  Louise R Rodino-Klapac; Jerry R Mendell; Zarife Sahenk
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

10.  Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction.

Authors:  Mathias Tremp; Souzan Salemi; Remo Largo; Karl-Erik Andersson; Jan A Plock; Jan Plock; Tamer Aboushwareb; Tullio Sulser; Daniel Eberli
Journal:  World J Urol       Date:  2013-11-12       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.